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Serotonin receptors as 
cardiovascular targets 
Carlos M. Villalh, Peter de Vries and Pramod R. Saxena 
Serotonin exerts complex effects in the cardiovascular 
system, including hypotension or hypertension, vaso- 
dilatation or vasoconstriction, and/or bradycardia or 
tachycardia; the eventual response depends primarily on 
the nature of the 5-HT receptors involved. In the light of 
current 5-HT receptor classification, the authors re- 
analyse the cardiovascular responses mediated by 5-HT 
receptors and discuss the established and potential 
therapeutic applications of 5-HT ligands in the treatment 
of some cardiovascular pathologies. 
S 
erotonin (5-hydroxytryptamine, 5-HT), a biogenic 
monoamine widely distributed in the animal and 
plant kingdoms, exerts complex effects in the 
periphery and in the central nervous system. 
Although the effects attributable to 5-HT have been known 
since the 19th century l2, its physiological and pathophysio- 
logical importance, including its role in cardiovascular regu- 
lation, remain unclear3.*. However, in many respects, 5-HT 
would seem an ideal neurohumoral transmitter candidate 
for the cardiovascular system. Secreted from enterochromaf- 
fin cells into the blood, 5-HT is stored by platelets. During 
aggregation, usually at a site of vascular injury, platelets 
release 5-HT, thus providing a unique mechanism for local 
delivery. Moreover, circulating 5-HT can be taken up by 
sympathetic neurons and vascular endothelial cells and 
could, subsequently, be coreleased5,“. 
Classification and nomenclature of 5HT 
receptors 
The first vital step towards characterizing 5-HT receptors 
was undoubtedly that undertaken in 1957 by Gaddum 
and Picarelli’, who reported the existence of musculotropic 
‘D’ and neurotropic ‘M’ receptors for 5-HT in the guinea- 
pig ileum. However, subsequent evidence showed that 
some musculotropic responses to 5-HT could not be placed 
within this schemex. Then, in 1979, Peroutka and Snyder 
challenged this classification, showing the existence of 
5-HT, (low affinity for [3H]spiperone) and 5-HT, (high 
affinity for [3Hlspiperone) binding sites in cerebral 
membraness. The advent of ketanserinlo confirmed that the 
5-HT, site corresponded to most ‘D’ receptors. The 
Serotonin Club Nomenclature Committee built upon 
this information and, on the basis of the conjunction of 
structural (amino acid sequence), transductional (receptor 
coupling) and operational (drug-related) criteria, 5-HT 
receptors are now categorized into five main type&-l3 (see 
Table 1): 
l 5-HT,. which corresponds to some ‘D’ receptors and 
5-HT, binding sites and can be subdivided into func- 
tional subtypes 5-HT,,, 5-HT,, (previously 5-HT,,$ and 
5-HT,, (previously 5-HT,,,); 
l 5-HT,, which corresponds to most ‘D’ receptors and 
5-HT, binding sites and can be subdivided into 5-HTzh, 
5-HT,, and 5-HT,, subtypes: 
l 5-HT,, which is equivalent to ‘M’ receptors; 
l 5-HT,; 
l 5-HT,. 
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Table 1. Classification of 5HT receptorsa,b 
Receptor 
5-HT,, 
5-HT, ac 
5-HT, a~ 
5-ht,, 
5-ht, r 
5-HT,, 
5-HT,, 
5-HT,, 
5-HT, 
5-HT, 
5-ht54/5B 
5-ht, 
5-HT, 
Agonists 
8-OH-DPAT 
Antagonists 
WAY100135 
5-CT>5-HT>sumatriptan 
5-CTz5-HT>sumatriptan 
5-HT 
5-HT, sumatriptan 
GR127935 
GRI 27935 
Methiothepin 
Methysergide 
cr-Methyld-HT, DOI Ketanserin 
a-Methyld-HT, DOI SB200646 
a-MethylEHT, DOI 
2-Methyld-HT; 
5-MeOT inactive 
5-MeOT, renzapride 
Mesulergine 
Ondansetron, 
tropisetron 
GRI 13808 
5-HT, ergotamine LSD 
5-MeOTz5-HT>5-CT; Methiothepin, 
sumatriptan inactive clozapine 
5-CT>>S-HTr5-MeOT> Mesulergine, 
8-OH-DPAT; sumatriptan methiothepin, 
inactive clozapine 
Transduction 
f-1 Adenylate cyclase 
f-1 Adenylate cyclase 
(-1 Adenylate cyclase 
(-1 Adenylate cyclase 
(-1 Adenylate cyclase 
(+I Phospholipase C 
(+) Phospholipase C 
(+I Phospholipase C 
Na+/K+ channel 
(+I Adenylate cyclase 
? 
(+I Adenylate cyclase 
(+I Adenylate cyclase 
Localization 
Raphe nucleus 
Cranial blood vessels 
Presynaptic neurons 
Cortex 
CNS, periphery (?I 
Smooth muscle, 
platelets 
Rat fundus, 
endothelium of 
some blood vessels 
Choroid plexus 
Peripheral nerves 
Gastrointestinal tract, 
pig and human atrium 
CNS 
CNS 
CNS, smooth muscle, 
cat atrium 
Function 
Autoreceptor, centrally 
mediated 
hypotension 
Vasoconstriction 
Autoreceptor 
Unknown 
Vasoconstriction (?I, 
inhibition of plasma 
extravasation (?I 
Contraction, 
aggregation 
Contraction, release of 
nitric oxide 
CSF production (?I 
(+I Neuronal activity 
(+I Neuronal activity, 
positive inotropy and 
inotropy 
Unknown 
Unknown 
Circadian rhythm, 
relaxation, positive 
inotropy and 
chronotropy 
aModifIed from Saxena and Vrllalons and Hover et a/.‘*. 
KNS, central nervous system; CSF, cerebrosprnal flurd; DOI. 1-(2,5-dimethoxy-4-rodophenyl)-2-am1nopropane; 8-OH-DPAT, 8-hydroxy-2-idr-n-propylamrno)tetralin; LSD, 
lysergrc acid diethylamrde, 5-MeOT, 5methoxytryptamine; 5-CT, 5-carboxamidotryptamrne; (-), decrease, (+I. Increase. 
CThe human 5-HT,,,,, receptors are so far pharmacologrcally indrstrngurshable. However, the rodent homologue (r5-HT,,) has a drfferent pharmacological profrle (agonist: 
CP93129; antagonist: SD221 009) 
In addition, this current classification includes certain 
recombinant (5-ht,,, 5-ht,,, 5-ht,,, 5-ht,, and 5-h@ and 
‘orphan’ receptors awaiting definitive characterization. 
It is noteworthy that the arrival of sumatriptanr* led to the 
subdivision of 5-carboxamidotryptamine-sensitive 5-HT,- 
like receptors into 5-HT,, (sumatriptan-sensitive) and 
5-HT,, (sumatriptan-insensitive) receptord. Utilizing their 
differential coupling to adenylate cyclase and employing 
new cloning techniques, it was shown that j-HT,, (vaso- 
constrictor) and j-HT,, (vasodilator) receptors are different 
and appear to correspond to j-HTrB1rD (Refs 15,16) and 
j-HT, (Ref. 17) receptors, respectively. 
Cardiovascular responses mediated by 5-HT receptors 
The effects of 5-HT in the cardiovascular system are com- 
plex because they consist of bradycardia or tachycardia, 
hypotension or hypertension, and vasodilatation or vaso- 
constriction. Considering the above classification criteria, 
the cardiovascular effects of j-HT are mediated by five main 
sets of receptors: j-HT, (5-HT,, and 5-HT,,&, 5-HT,, 
5-HT,, j-HT, and 5-HT, (Refs 3,4,15-20). 
Intravenous injection of j-HT usually lowers heart rate via 
the von Bezold-Jarisch reflex, mediated by 5-HT, receptors 
on sensory vagal nerves in the heart, When this reflex is sup- 
pressed (e.g. by vagotomy or spinal section), 5-HT increases 
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the heart rate in different species by a variety of direct and 
indirect mechanisms*,r8.21, including: 
l myocardial 5-HT, (rat), 5-HT, (human, pig) and 5-HT, 
(cat) receptors; 
l neurotropic 5-HT, (rabbit) receptors; and 
l tyramine-like (guinea-pig) or unknown (mollusc) mecha- 
nisms. 
On the other hand, the blood pressure response to 5-HT 
is usually triphasic and consists of an initial short-lasting 
hypotension caused by bradycardia (von Bezold-Jarisch 
reflex), a middle pressor phase and a late, longer-lasting, 
hypotension. The pressor response is a result of vaso- 
constriction mediated mainly by 5-HT, receptors3. Finally, 
the late depressor response may involve four different 
mechanisms: 
l stimulation of central 5-HT,,\ receptors, producing a de- 
crease in sympathetic and an increase in vagal activityQ23; 
l activation of prejunctional sympathoinhibitory 5-HT,a,,, 
l activation of 5-HT, receptors on vascular smooth 
muscle17.20.26; and 
l stimulation of certain receptors on vascular endothelium 
(5-HT,, in some blood vessels), resulting in the release 
of a relaxant factor, probably nitric oxider2.2’. 
In addition, 5-HT-induced constriction in a number of 
blood vessels, particularly the large arteries and arterio- 
venous anastomoses of the cranial extracerebral region (e.g. 
human middle meningeal arteryzx-Jo and pig and dog exter- 
nal carotid arterial bed’?), is mediated by j-HT,,,,, (most 
likely 5-HT,,$ receptors. Although mRNA for the 5-ht,, 
receptor has been located in the human middle meningeal 
artery29, activation of this receptor does not appear to con- 
tribute to 5-HT- or sumatriptan-induced contractions of this 
vesseljo. 
5-HT-related drugs in cardiovascular pathologies 
The cardiovascular pharmacology of 5-HT suggests that 
compounds acting on 5-HT receptors can be employed for 
therapeutic use in the treatment of migraine, hypertension 
and some peripheral vascular diseasesA,+z3i-33. In particular, 
the recent recognition of the 5-HT, receptor as a functional 
receptor will undoubtedly disclose more therapeutic possi- 
bilities. Indeed, a large number of pharmaceutical companies 
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are currently interested in serotonergic drugs+, and the 
patenting activity indicates that these companies expect to 
convert new chemical entities into marketable products for 
therapeutic use. The established, as well as some potential, 
therapeutic uses of 5-HT receptor agonists and antagonists 
are listed in Table 2. 
Migraine 
Many studies have conclusively shown that sumatriptan, an 
agonist at the 5-HT,,;,, receptors mediating constriction of 
cranial large arteries and arteriovenous anastomosesi*,rj,34, is 
effective in aborting migraine attackG3j. The success of this 
drug has prompted a large number of pharmaceutical com- 
panies to develop novel 5-HT,,,,, receptor agonists* 
(Table 2). In particular, efforts are being directed towards 
making more lipid-soluble and selective compounds to im- 
prove oral bioavailability and to avoid coronary artery vaso- 
constriction. Although the new 5-HT,,,,, receptor agonists 
such as rizatriptan, zolmitriptan and naratriptan (Figure 1 
and Table 3) appear to have a better oral bioavailability33, 
they do not seem to differ with respect to their coronary side 
effect potentiap6. 
We believe that vasoconstriction in the extracerebral 
(intra- and extracranial) blood vessels, which appear to be 
dilated during migraine, is mainly responsible for the thera- 
peutic effect of sumatriptan33. However, other mechanisms, 
such as inhibition of central trigeminal neuron@ or neuro- 
genie plasma extravasation38, have also been suggested. 
Phebus and coworkers39 have argued that the inhibition of 
plasma extravasation as well as the therapeutic activity of 
sumatriptan is mediated via the 5-ht,, receptor. Therefore, 
they surmise that LY334370 (Figure l), which lacks vaso- 
constrictor activity (on rabbit saphenous vein) but has a 
selective agonist action at the 5-ht,, receptor (Table 3) and 
blocks plasma extravasation following trigeminal nerve 
stimulation, may potentially be a better antimigraine agent 
than sumatriptan3”. However, in our opinion, the following 
facts do not support the above hypothesis: 
l Some compounds, such as neurokinin NK, and endo- 
thelin ET,,a receptor antagonists and CP122288 (Figure 1 
and Table 3), all of which potently inhibit plasma 
extravasation4w2, failed to show clinical efficacy in 
migraine4*6. 
l Sumatriptan (~4: 7.63, 7.94) has a higher affinity than 
ergotamine (~4: 6.76) for the i-ht,, receptor (N. Adham 
et al.+‘; PJ. Pauwels, pers. commun.), yet sumatriptan is 
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Table 2. Therapeutic uses of serotonergic drugs in cardiovascular diseasesa 
Acute migraine 
5-HT lB/lD agonist 
5-HT,,,,, agonist 
5-HT,B,,D agonist 
5-HT , B,1 D agonist 
5-HT , B,1 D agonist 
5-HT 1 B,1 D agonist 
5-HT, B,1 o agonist 
5-HT, F agonist 
Migraine prophylaxis 
5-HT ,e,,n agonist/BHT, antagonist 
5-HT, antagonist 
5-HT,, antagonists 
Essential hypertension 
5-HT,, agonist/q antagonist 
5-HT, antagonist/a, antagonist 
5-HT, agonists 
Pulmonary hypertension 
5-HT, antagonist/q antagonist 
Portal hypertension 
5-HT, antagonist/a, antagonist 
Eclampsia of pregnancy 
5-HT, antagonist/q antagonist 
Carcinoid syndrome 
5-HT, antagonist/q antagonist 
Cardiac arrhythmia 
5-HT, antagonists 
Peripheral vascular diseases 
5-HT, antagonist/a, antagonist 
5-HT, agonists 
Skin transplantation 
5-HT, agonists 
Cerebral ischaemia 
5-HT,, agonists 
Drug 
Sumatriptan 
Naratriptan 
Zolmitriptan 
Rizatriptan 
Eletriptan 
Alniditan 
SB209509 
LY334370 
Methysergideb 
Pizotifenb 
Urapidilc 
Ketanserinc 
Ketanserinc 
Ketanserinc 
Ketanserinc 
Ketanserin 
Ketanserin 
Company 
Glaxo Wellcome 
Glaxo Wellcome 
Zeneca 
Merck 
Pfizer 
Janssen 
SmithKline Beecham 
Lilly 
Novartis 
Novartis 
Bvk 
Janssen 
Janssen 
Janssen 
Janssen 
Janssen 
Status 
Marketed 
Clinical Phase III 
Clinical Phase III 
Clinical Phase IIB 
Clinical Phase IIB 
Clinical Phase IIA 
Clinical Phase IIA 
Clinical Phase IIA 
Marketed 
Marketed 
Questionable 
Marketed 
Marketed 
Worth exploring 
Sometimes used 
Questionable 
Questionable 
Questionable 
Unlikely 
Questionable 
Worth exploring 
Worth exploring 
Unlikely 
aModified from Saxena4 and Saxena and Ferra@ 
b5-HT, receptor antagonlst activity IS probably not Involved In therapeutic actlon. 
a less potent antimigraine agent on the basis of parenteral 
doses used in migraine (sumatriptan: 6 mg, subcuta- 
neously; ergotamine: 0.25-0.5 mg, intramuscular). 
l The inhibitory action of sumatriptan on plasma extra- 
vasation, but not of CP122288, is blocked by GR127935 
(Ref. 48); this latter compound has a high affinity for 
5-HTIB11n receptors (~4: 9.9/8.9)“‘, but not for the i-ht,, 
receptor (pKj: 7.1; H. Connor, per-s. commun.). 
l The 5-HT,,,,n receptor agonists rizatriptan and alniditan 
(Figure l), which are effective in migraineso, have little 
affinity for the 5-ht,, receptor (Table 3)5l. 
l The contraction of the human middle meningeal artery 
by sumatriptan seems to be mediated by the 5-HT,, (not 
5-h@ receptor30, indicating that the antimigraine activity 
of sumatriptan-like drugs is dependent upon their 
affinity for the 5-HT,, receptor. 
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H 
Sumatriptan ,W 
Naratriptan 
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H 
Eletriptan 
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Rizatriptan 
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H3C, 
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CP122288 
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LY334370 
Figure 1. Sumatriptan and neu.: 5-HT,,, and 5-h,, receptor 
agonists under investigation for the treatment of migraine headaches. 
Whether an agonist action at the 5-ht,, receptor can also con- 
fer antimigraine action remains to be seen, and the results of 
clinical trials with LY334370 are awaited with interest. 
Some antimigraine drugs (methysergide, pizotifen, ergota- 
mine, dihydroergotamine) are potent antagonists at 5-HT, 
receptors, but many other 5-HT,, antagonists (ketanserin, 
cyproheptadine, mianserin, methiothepin) are not of much 
use in migraine therapyjz. More recently, it has been pro- 
posed that 5-HT,, 2c receptors may be involved in the initi- 
ation of migraine attacksz’,j3.j4. Thus, selective antagonism of 
these receptors, in particular the 5-HT,, receptor, which may 
mediate nitric oxide release from vascular endotheliumi2.27, 
should be effective in migraine preventionj3,j*. However, as 
already discussed elsewherej*. several 5-HTzB1,c receptor 
antagonists, including mianserin and cyproheptadine, are 
not very effective antimigraine agents. It seems, therefore, 
that additional properties, such as vasoconstriction in the 
extracerebral cephalic circulation in the case of methy- 
sergide, ergotamine and dihydroergotamine (partly via 
Systemic, pulmonary and portal 
hypertension 
Both urapidil (5-HT,, receptor agonist) and 
ketanserin (5-HT,, receptor antagonist) are 
approved for the treatment of systemic hyper- 
tension Indeed, it is claimed that these drugs 
decrease blood pressure by stimulating 5-HT,, 
receptors located centrally in the nucleus tractus 
solitarii (urapidil) or by blocking 5-HT,, recep- 
tors mediating peripheral vasoconstriction 
(ketanserin). However, as discussed in detail elsewherej, it 
seems that such effects are not involved to a significant degree 
in the clinical effects of these drugs; both urapidil and 
ketanserin have a potent a,-adrenoceptor antagonist activity, 
which can adequately explain their antihypertensive effect, 
In view of the arteriolar vasodilatation mediated by the 
5-HT, receptorj9. it may be worthwhile exploring selective 
agonists at this receptor as antihypertensive agents. In this 
regard, however, one should be aware of the competition 
with excellent drugs already available. 
In the complex setting of cardiac surgery and cardio- 
pulmonary bypass, several potent mediators are released, 
which, in turn, may produce systemic and/or pulmonary 
hypertension. One of the mediators may be 5-HT, released 
from aggregating platelets, causing vasoconstriction by 
activating 5-HT, receptors, particularly in patients with 
an impaired endothelial function (e.g. atherosclerosis@). 
Ketanserin has proved effective in the treatment of post- 
operative pulmonary hypertension61. It is far from clear, 
5-HTnm receptors) and antidepressant action 
in the case of pizotifen, may be necessary for 
therapeutic actionjj. Similarly, because no clear- 
cut positive antimigraine effect has been found 
for any of the 5-HT, receptor antagonists@s’, 
this receptor does not appear to play a major 
role in migraine. 
Lastly, it may be pointed out that the constric- 
tion of porcine carotid arteriovenous anastomoses 
elicited by ergotamine, dihydroergotamine or 
5-HT (the latter in the presence of ketanserin) is 
not very susceptible to blockade by GR127935. 
This suggests the involvement of a receptor 
other than the 5-HTz, and 5-HTIB1iD receptor@. 
It will be interesting to characterize this receptor 
further and explore whether it can be a target 
for developing novel antimigraine drugs. 
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Table 3. p&values at cloned human receptors for 
sumatriptan and some new 5-HT,,,,, and 5-ht,, 
receptor agonists under investigation for the 
treatment of migraine headachesa 
5-HT, receptors is somewhat questionable. However, in 
this context, selective 5-HT7 receptor antagonists may be 
expected to be effective. 
Compound 5-HT,, 
Sumatriptan 8.50 
Naratriptan 9.33 
Eletriptan 8.00 
Zolmitriptan 9.08 
Rizatriptan 8.14 
Alniditan 8.96 
CP122288 8.16 
LY334370 6.86 
5-HT,, 5-h& 
8.68 7.94 
9.16 8.40 
8.94 8.18b 
9.66 7.54 
8.63 6.86 
9.40 6.44 
7.53 8.48b 
6.90 8.96 
Cardiac disorders 
5-HT, receptors mediate increases in the rate and contractil- 
ity of the human atrium (see above). Because 5-HT can 
induce arrhythmias in the human isolated atrium, it is pro- 
posed that 5-HT, receptor antagonists could be useful in the 
treatment of cardiac arrhythmia@. However, the role of 
5-HT, if any, in the pathogenesis of cardiac arrhythmias has 
not been established. Thus, it seems unlikely that such drugs 
will be effective in this disorder. 
a Affinity constant data are from Dr P.J. Pauwels (pers. commun.), except for 
eletriptan. CP122288 (both Pfizer. UK). alntditan5’ and LY334370 (Ref. 39) 
b Value for the rat receptor. 
however, whether 5-HT, receptor blockade is responsible 
for the effectiveness of ketanserin, since no selective 5-HT, 
receptor antagonists have been shown to be effective. 
On the other hand, the ability of 5-HT, receptor agonists 
to increase atria1 contractility suggested that these drugs may 
have application in the therapy of heart failure. Any such 
hopes were dashed, however, when it was shown that 
5-HT, receptors are not present on human ventricles65.66. 
Perhaps less questionable is the role of 5-HTz receptors in 
some cases of portal hypertension, where higher levels of 
free plasma 5-HT are found in the portal venous circu- 
lation3*. This assumption is based on the fact that both 
ketanserin (which combines 5-HT, with a,-adrenoceptor 
blockade) and ritanserin (at doses without a,-adrenoceptor 
blockade) lower portal venous pressureb2. 
Peripheral vascular diseases 
Pre-eclampsia and eclampsia 
Ketanserin has been shown to be effective in the treatment 
of pre-eclampsia and eclampsia, pathologies that seem to 
involve local release of 5-HT from aggregating platelets in 
the placental circulation32.63. Although this finding does not 
establish the involvement of 5-HT, receptors, this hypoth- 
esis could be substantiated by establishing the effectiveness 
of selective 5-HT, receptor antagonists. 
5-HT has been implicated in the pathophysiology of periph- 
eral vascular diseases, but the evidence is not compelling67. 
Although some clinical trials show a moderate efficacy of 
ketanserin”‘, this drug is not registered for this indication in 
The Netherlands. However, it is interesting to note that one 
of the prominent cardiovascular effects of 5-HT is its ability 
to produce vasodilatation via stimulation of 5-HT, recep- 
tors17,20. Therefore, selective agonists at vascular 5-HT, 
receptors may be expected to enhance capillary blood flow 
and be useful in the treatment of peripheral vascular dis- 
eases, including trophic skin ulcers. This approach might 
also have potential applications, as yet unexplored, in the 
medical treatment of skin grafts and baldness. 
Cerebral ischaemia 
Carcinoid syndrome 
The carcinoid syndrome is a pathology characterized pre- 
dominantly by gastrointestinal alterations (e.g. diarrhoea) 
and facial flushing, provoked by a tumour secreting a gross 
excess of several mediators, including 5-HT (Ref. 31). 
Ketanserin has been claimed to be effective in diminishing 
the frequency and severity of some manifestations of this 
syndrome, including diarrhoea and flushings*. Nevertheless, 
considering that 5-HT-induced arteriolar vasodilatation is 
mediated mainly by 5-HT, receptors5”, the clinical effective- 
ness of ketanserin in relieving facial flushing by blockade of 
Buspirone and ipsapirone, established anxiolytic agents with 
an action at central 5-HT,, receptors+, decrease infarct size 
in animal models of focal”8 and global”” cerebral ischaemia. 
Notwithstanding, the involvement of 5-HT,, receptors is 
questionable because these drugs are nonselective agents 
and, most significantly, Shydroxy-2-(di-n-propylamino)- 
tetralin (S-OH-DPAT). which is also a potent 5-HT,, receptor 
agonist12, was ineffective in these experimental models6~70. 
Closing remarks 
During the last decade, research in the field of 5-HT has 
been boosted by the availability of potent and selective 
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drugs. These drugs and the increasing understanding of 
transduction mechanisms, as well as the structure of the 
receptor protein, have enabled a more meaningful charac- 
terization and nomenclature of 5-HT receptors, Thus, five 
main classes with several subtypes (5-HT,, 5-HT,, 5-HT,, 
5-HT, and 5-HT,) as well as some not yet adequately 
characterized recombinant (e.g. 5-ht,,, 5-ht,,, j-ht,,, 5-ht,,, 
5-ht,) and ‘orphan’ 5-HT receptors have been recognized, 
Indeed, the molecular cloning and expression of a growing 
number of 5-HT receptors in host cells now offers the possi- 
bility to screen new molecules easily. This will help identify 
selective ligands, which could, in turn, provide access 
to better drugs for a more efficient treatment of human 
ailments. 
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